Lactulose hydrogen breath test findings in children and adolescents with duodenogastric reflux and suspected small intestinal bacterial overgrowth: a pilot study
Open Access
- 15 October 2026
- journal article
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 56 (5) , 1462-1469
Abstract
Background/aim: This study aimed to identify small intestinal bacterial overgrowth (SIBO) in children and adolescents with persistent symptoms of duodenogastric reflux disease (DGRD). Materials and methods: Patients aged 5–18 years who were diagnosed with DGRD between 2021 and 2023 were identified. Patients with two or more of 10 symptoms suggestive of SIBO (nausea, vomiting, weight loss, diarrhea, fatigue, joint pain, bloating, depression, acne rosacea, malnutrition) underwent lactulose hydrogen breath testing (LHBT). Results: A total of 112 patients with DGRD were identified. Seven patients who could not be reached via the telemedicine method were excluded from the study. LHBT was not performed for 76 patients because they had one or fewer symptoms and nine patients did not want to participate in the study. Twenty children suspected of having SIBO were invited to the hospital. The most common SIBO symptoms in these patients were fatigue, nausea, and depression. SIBO positivity was assessed in two patients who exhibited an increase of ≥20 ppm in breath hydrogen measurements up to the 90th minute following basal breath tests and the ingestion of 15 mL of lactulose. Two patients diagnosed as having SIBO had normal control LHBT values after two doses of 10 mg/kg/day rifaximin treatment. Of the 17 patients with negative LHBT results, 12 received empirical rifaximin treatment (10 mg/kg twice daily) due to clinical symptoms suggestive of SIBO, and clinical improvement was achieved in 10 patients. Eighty-five percent of patients who received rifaximin experienced symptom normalization. Conclusion: SIBO should be considered in children and adolescents with DGRD who have persistent symptoms, given that dysmotility is a common etiological factor.Keywords
This publication has 26 references indexed in Scilit:
- Small intestinal bacterial overgrowth in children: An expert review by the ESPGHAN Gastroenterology CommitteeJournal of Pediatric Gastroenterology and Nutrition, 2025
- Content validation of a daily patient-reported outcome measure for assessing symptoms in patients with Small Intestinal Bacterial OvergrowthQuality of Life Research, 2023
- European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensusUnited European Gastroenterology Journal, 2021
- Small intestinal bacterial overgrowth in systemic sclerosis: a review of the literatureArchives of Dermatological Research, 2018
- Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokineticsJGH Open, 2018
- Scintigraphy Demonstrates High Rate of False-positive Results From Glucose Breath Tests for Small Bowel Bacterial OvergrowthClinical Gastroenterology and Hepatology, 2016
- Breath Testing for Small Intestinal Bacterial Overgrowth: Maximizing Test AccuracyClinical Gastroenterology and Hepatology, 2014
- Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2009
- Production, metabolism, and excretion of hydrogen in the large intestineGastroenterology, 1992
- Comparison of the 1-gram [14C]xylose, 10-gram lactulose-H2, and 80-gram glucose-H2 breath tests in patients with small intestine bacterial overgrowthGastroenterology, 1986